glp-1 market news november 2025 Receptor Agonist Size & Share Report, 2032 GLP-1 Receptor Agonist Market Valued

Lower costs by requiring manufacturers to provide an MFN-based supplemental rebate in addition to the standard Medicaid Drug Rebate Program (MDRP)

In this white paper well look at the impact of these announcements through five key lenses: The scope of the announcements what do we know now

Sugary drinks and ultra-processed snacks waste your limited calorie budget on foods that do not support lean mass

Despite similar AUD treatment rates, patients with sAH were significantly more likely to achieve early alcohol abstinence (82.2% versus 65.8%, p=0.016), and less likely to return to drinking when compared to patients with mAH (54.1% versus 72.9%

What's the difference between compounded and FDA-approved GLP-1 medications